Eva Cavallin‐Ståhl

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

Jeanette Lundin, Hans Hagberg, Roland Repp et al. · Blood · 2003 · 389 citations · Full text

Life Sciences, Immunology, Oncology +9

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

J. Beyer, Peter Albers, Renske Altena et al. · Annals of Oncology · 2012 · 322 citations · Full text

Medicine, Oncology, Cancer Survivorship Care +10

Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program

Torgrim Tandstad, Olav Dahl, Gabriella Cohn‐Cedermark et al. · Journal of Clinical Oncology · 2009 · 266 citations · Full text

Medicine, Oncology, Cancer Control +15

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

S. Krege, Rainer Souchon, Peter Albers et al. · European Urology · 2008 · 252 citations

Medicine, Cancer Biology, Oncology +17

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Torgrim Tandstad, Rune Smaaland, Arne Solberg et al. · Journal of Clinical Oncology · 2011 · 230 citations · Full text

Medicine, Oncology, Chemotherapy +15